×

Biotech buyout: The next big liver disease

3:28 PM ET Tue, 20 Sept 2016

Tobira Therapeutics shares surge after Allergan agrees to buy the drug developer for $1.7. CNBC's Meg Tirrell reports the details, as well as other biotech takeover targets surrounding progressive liver disease "NASH."